Merrion Pharmaceuticals Plc - Product Pipeline Review - 2014

Global Markets Direct
April 30, 2014
38 Pages - GMD12077
$1,500.00

Summary

Global Markets Direct’s, ‘Merrion Pharmaceuticals Plc - Product Pipeline Review - 2014’, provides an overview of the Merrion Pharmaceuticals Plc’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Merrion Pharmaceuticals Plc’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Merrion Pharmaceuticals Plc including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Merrion Pharmaceuticals Plc’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Merrion Pharmaceuticals Plc’s pipeline products

Reasons to buy

- Evaluate Merrion Pharmaceuticals Plc’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Merrion Pharmaceuticals Plc in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Merrion Pharmaceuticals Plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Merrion Pharmaceuticals Plc and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Merrion Pharmaceuticals Plc
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Merrion Pharmaceuticals Plc and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Merrion Pharmaceuticals Plc Snapshot 5
Merrion Pharmaceuticals Plc Overview 5
Key Information 5
Key Facts 5
Merrion Pharmaceuticals Plc - Research and Development Overview 6
Key Therapeutic Areas 6
Merrion Pharmaceuticals Plc - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Merrion Pharmaceuticals Plc - Pipeline Products Glance 12
Merrion Pharmaceuticals Plc - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
Merrion Pharmaceuticals Plc - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Merrion Pharmaceuticals Plc - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Merrion Pharmaceuticals Plc - Drug Profiles 16
zoledronic acid 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
alendronate sodium 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
MER-104 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
fondaparinux sodium 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
GIPET Technology Based Program-1 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
GIPET Technology Based Program-2 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Partnered Program-1 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Partnered Program-2 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Partnered Program-3 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
UEA-1 Mimetics 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Merrion Pharmaceuticals Plc - Pipeline Analysis 28
Merrion Pharmaceuticals Plc - Pipeline Products by Target 28
Merrion Pharmaceuticals Plc - Pipeline Products by Route of Administration 30
Merrion Pharmaceuticals Plc - Pipeline Products by Molecule Type 31
Merrion Pharmaceuticals Plc - Pipeline Products by Mechanism of Action 32
Merrion Pharmaceuticals Plc - Recent Pipeline Updates 34
Merrion Pharmaceuticals Plc - Dormant Projects 35
Merrion Pharmaceuticals Plc - Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Tables
Merrion Pharmaceuticals Plc, Key Information 5
Merrion Pharmaceuticals Plc, Key Facts 5
Merrion Pharmaceuticals Plc - Pipeline by Indication, 2014 7
Merrion Pharmaceuticals Plc - Pipeline by Stage of Development, 2014 8
Merrion Pharmaceuticals Plc - Monotherapy Products in Pipeline, 2014 9
Merrion Pharmaceuticals Plc - Partnered Products in Pipeline, 2014 10
Merrion Pharmaceuticals Plc - Partnered Products/ Combination Treatment Modalities, 2014 11
Merrion Pharmaceuticals Plc - Phase III, 2014 12
Merrion Pharmaceuticals Plc - Phase II, 2014 13
Merrion Pharmaceuticals Plc - Phase I, 2014 14
Merrion Pharmaceuticals Plc - Preclinical, 2014 15
Merrion Pharmaceuticals Plc - Pipeline by Target, 2014 29
Merrion Pharmaceuticals Plc - Pipeline by Route of Administration, 2014 30
Merrion Pharmaceuticals Plc - Pipeline by Molecule Type, 2014 31
Merrion Pharmaceuticals Plc - Pipeline Products by Mechanism of Action, 2014 33
Merrion Pharmaceuticals Plc - Recent Pipeline Updates, 2014 34
Merrion Pharmaceuticals Plc - Dormant Developmental Projects,2014 35
Merrion Pharmaceuticals Plc, Subsidiaries 36

List of Figures
Merrion Pharmaceuticals Plc - Pipeline by Top 10 Indication, 2014 7
Merrion Pharmaceuticals Plc - Pipeline by Stage of Development, 2014 8
Merrion Pharmaceuticals Plc - Monotherapy Products in Pipeline, 2014 9
Merrion Pharmaceuticals Plc - Pipeline by Top 10 Target, 2014 28
Merrion Pharmaceuticals Plc - Pipeline by Top 10 Route of Administration, 2014 30
Merrion Pharmaceuticals Plc - Pipeline by Top 10 Molecule Type, 2014 31
Merrion Pharmaceuticals Plc - Pipeline Products by Top 10 Mechanism of Action, 2014 32

$1,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax